English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Cervical cancer in the 3rd trimester of pregnancy is rare and the management is thorny. The disease control and fetal outcome are cautiously considered by the clinicians. Case presentation: A 36-year-old Han Chinese female with cervical cancer staged as IB1 at the gestational age of 30 + 3 weeks was referred to our department. The patient and the family refused to term pregnancy and wanted pregnancypreserving management, she was treated by neoadjuvant chemotherapy with paclitaxel 230 mg plus nedaplatin 120 mg first, and caesarean section; radical hysterectomy and pelvic lymph node dissection were performed three weeks later. Based on the pathology report, the patient underwent further radiotherapy, and the neonate was healthy. Conclusions: The patient with cervical cancer diagnosed in the 3rd trimester of pregnancy can be performed with neoadjuvant chemotherapy (Paclitaxel/nedaplatin) before operation, while the proper chemotherapy doses must be carefully studied considering the pharmacokinetic alteration during pregnancy and the adverse effects for the pregnant patient and the fetus. Thus, further investigation is required regarding the safety and outcome.

Neoadjuvant Chemotherapy with Paclitaxel and Nedaplatin plus Radical Surgery in Cervical Cancer during Pregnancy: A Case Report and Review of the Literature